Sydney Eye Hospital Cohort 5-year follow-up
| DEX-implant (27 eyes) | Bevacizumab (27 eyes) | P value | |
| Baseline mean BCVA (SD) | 51.3 (15.3) | 62.4 (10.1) | 0.064 |
| Mean BCVA 2-year (SD) | 60.7 (17.5) | 71.1 (13.1) | 0.113 |
| Mean BCVA 5-year (SD) | 55.6 (14.6) | 66.8 (9.2) | 0.091 |
| Mean change in BCVA (5 years) (SD) | 4.3 (11.3) | 4.4 (9.2) | 0.788 |
Of the 54 eyes that enrolled in the BEVORDEX trial, 27 eyes from each treatment group attended clinic visit for BCVA at 5 years. Baseline refers to BEVORDEX trial enrolment.
BCVA, best corrected visual acuity; DEX, dexamethasone.